Emergent BioSolutions | EBS - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amarin USD 51.48M 113K 2025-12
ANI Pharmaceuticals USD 597.21M 34.91M 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Coherus Biosciences USD 51.83M 2.48M 2025-12
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Exelixis USD 380.28M 20.8M 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
Lonza CHF 2.9B 184M 2025-06
Merck USD 15.77B 2.4B 2026-06
Moderna USD 960M 817M 2026-06
Myriad Genetics USD 212.8M 16.2M 2025-12
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Pacira USD 180.54M 7.79M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 211.54M 15.12M 2026-06
Sanofi EUR 9.92B 607M 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
United Therapeutics USD 6.4B 499.2M 2026-06
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12